Key result
Twice-daily aspirin for acute coronary syndrome with suspected aspirin resistance may be an excessive dosing strategy without clear clinical benefit.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This is an editorial discussing the ANDAMAN trial on twice-daily aspirin dosing for acute coronary syndrome with suspected aspirin resistance.
This editorial refers to ‘Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial’, by J.-G. Dillinger et al., ht
No takes yet. Share an insight, caveat, or question.
McCarthy et al. (2025) studied this question. Twice-daily aspirin for acute coronary syndrome with suspected aspirin resistance may be an excessive dosing strategy without clear clinical benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: